Needham Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $78
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and lowers the price target from $80 to $78.
Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and lowers the price target from $80 to $78.